Halozyme (HALO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$110.19-0.51%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
Halozyme grows revenue about 21% yearly, reaching ~$1.15B in 2026. Profit improves with operating income rising to $184M by Q1 2026. Cash from operations strengthens to $180M, supporting growth and investments. The stock trades cheap with a PE below peers and solid free cash flow yield.
Earnings have missed recently, showing execution risks. The COO departure may disrupt operations. Revenue growth or profit margins could slow, hurting cash flow and valuation.
The price is about 16% below our fair value near $96, reflecting roughly 21% revenue growth expected by analysts. Our fair value is slightly above the Street median, indicating the market fairly prices current growth but leaves some upside.
Breaks if: Cash from operations falls below $180M in FY26
Breaks if: Further key management departures or failure to meet guidance
Breaks if: Operating income growth stalls or declines below prior trend in FY26
Breaks if: YoY revenue growth falls below ~20.9% in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on revenue and operating income growth. The current thesis state is stable, supported by strong recent results and a favorable sector backdrop.
The market appears to have a neutral valuation stance on HALO, with expectations slightly below what recent performance suggests. The stock is priced with a low fragility tier, indicating that there are no immediate concerns affecting its stability.
Management is on track to enhance revenue growth, operating income, and cash from operations, which are all key priorities. Recent financial performance has been strong, but there is a moderate risk of missing expectations given the high miss rate in the industry.
The long-term thesis hinges on maintaining revenue growth and operating income while navigating potential sector challenges. Key factors include the performance of sector bellwethers and any changes in guidance or economic conditions that could impact investor sentiment.
Overall, HALO's fundamentals are strong, but attention should be paid to external factors that could affect performance. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no current threats to the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.